CN1391609A - 用复制缺陷腺病毒载体加强cd8+t细胞对抗原的免疫应答 - Google Patents
用复制缺陷腺病毒载体加强cd8+t细胞对抗原的免疫应答 Download PDFInfo
- Publication number
- CN1391609A CN1391609A CN00815933A CN00815933A CN1391609A CN 1391609 A CN1391609 A CN 1391609A CN 00815933 A CN00815933 A CN 00815933A CN 00815933 A CN00815933 A CN 00815933A CN 1391609 A CN1391609 A CN 1391609A
- Authority
- CN
- China
- Prior art keywords
- antigen
- epitope
- cell
- individual
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 49
- 102000036639 antigens Human genes 0.000 title claims abstract description 49
- 108091007433 antigens Proteins 0.000 title claims abstract description 49
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 37
- 230000002950 deficient Effects 0.000 title claims abstract description 21
- 230000010076 replication Effects 0.000 title claims abstract description 21
- 230000028993 immune response Effects 0.000 title claims abstract description 8
- 239000013598 vector Substances 0.000 title claims abstract description 8
- 239000000203 mixture Substances 0.000 claims abstract description 60
- 241000700605 Viruses Species 0.000 claims abstract description 22
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 15
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 15
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 15
- 238000007918 intramuscular administration Methods 0.000 claims abstract description 10
- 230000037452 priming Effects 0.000 claims abstract 10
- 238000000034 method Methods 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 9
- 230000001939 inductive effect Effects 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 5
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 230000008901 benefit Effects 0.000 claims description 3
- 238000001727 in vivo Methods 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 description 33
- 230000036039 immunity Effects 0.000 description 28
- 241000701161 unidentified adenovirus Species 0.000 description 27
- 108020004414 DNA Proteins 0.000 description 26
- 241000699666 Mus <mouse, genus> Species 0.000 description 24
- 230000003053 immunization Effects 0.000 description 22
- 238000002649 immunization Methods 0.000 description 22
- 230000004044 response Effects 0.000 description 20
- 230000000890 antigenic effect Effects 0.000 description 16
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 230000001900 immune effect Effects 0.000 description 13
- 102100037850 Interferon gamma Human genes 0.000 description 12
- 108010074328 Interferon-gamma Proteins 0.000 description 12
- 230000028327 secretion Effects 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 241000224016 Plasmodium Species 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 210000004988 splenocyte Anatomy 0.000 description 9
- 108700005482 Protozoan circumsporozoite Proteins 0.000 description 8
- 230000005867 T cell response Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000009545 invasion Effects 0.000 description 8
- 230000002787 reinforcement Effects 0.000 description 8
- 210000003046 sporozoite Anatomy 0.000 description 8
- 238000011238 DNA vaccination Methods 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 201000004792 malaria Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 238000003018 immunoassay Methods 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000008521 reorganization Effects 0.000 description 4
- 239000013605 shuttle vector Substances 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 241000256186 Anopheles <genus> Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 101150052200 CS gene Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 241000700662 Fowlpox virus Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000223960 Plasmodium falciparum Species 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- -1 carrier Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 231100000284 endotoxic Toxicity 0.000 description 2
- 230000002346 endotoxic effect Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 229940065638 intron a Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- AJDIZQLSFPQPEY-UHFFFAOYSA-N 1,1,2-Trichlorotrifluoroethane Chemical compound FC(F)(Cl)C(F)(Cl)Cl AJDIZQLSFPQPEY-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 101000886418 Drosophila melanogaster GATA-binding factor C Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 238000002738 Giemsa staining Methods 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 108010028253 Measles virus nucleoprotein Proteins 0.000 description 1
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000009182 Parasitemia Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 241000223830 Plasmodium yoelii Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241001068295 Replication defective viruses Species 0.000 description 1
- 239000012891 Ringer solution Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 208000004006 Tick-borne encephalitis Diseases 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002223 anti-pathogen Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940023860 canarypox virus HIV vaccine Drugs 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- FEBNTWHYQKGEIQ-BIMULSAOSA-N nardin Natural products C[C@H]1CC[C@H](C=C(/C)C(=O)O)C2=C(C)CC[C@@H]12 FEBNTWHYQKGEIQ-BIMULSAOSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000009991 scouring Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003351 stiffener Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- FEBNTWHYQKGEIQ-UHFFFAOYSA-N valerenic acid Chemical compound CC1CCC(C=C(C)C(O)=O)C2=C(C)CCC12 FEBNTWHYQKGEIQ-UHFFFAOYSA-N 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9922361.2 | 1999-09-21 | ||
| GBGB9922361.2A GB9922361D0 (en) | 1999-09-21 | 1999-09-21 | Generating an immune response to an antigen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1391609A true CN1391609A (zh) | 2003-01-15 |
Family
ID=10861351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN00815933A Pending CN1391609A (zh) | 1999-09-21 | 2000-09-20 | 用复制缺陷腺病毒载体加强cd8+t细胞对抗原的免疫应答 |
Country Status (12)
| Country | Link |
|---|---|
| EP (2) | EP1612269A1 (enExample) |
| JP (1) | JP2003509470A (enExample) |
| CN (1) | CN1391609A (enExample) |
| AT (1) | ATE295421T1 (enExample) |
| AU (1) | AU762894B2 (enExample) |
| BR (1) | BR0014138A (enExample) |
| CA (1) | CA2384806A1 (enExample) |
| DE (1) | DE60020136T2 (enExample) |
| DK (1) | DK1214416T3 (enExample) |
| ES (1) | ES2241653T3 (enExample) |
| GB (1) | GB9922361D0 (enExample) |
| WO (1) | WO2001021201A2 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100410382C (zh) * | 2006-08-18 | 2008-08-13 | 上海交通大学医学院 | 一种可诱生细胞免疫应答的共表达载体和真核表达载体 |
| CN104755622A (zh) * | 2012-10-28 | 2015-07-01 | 巴法里安诺迪克有限公司 | 用于稳健t细胞和抗体应答的pr13.5启动子 |
| CN114828878A (zh) * | 2019-10-16 | 2022-07-29 | 癌症研究科技有限公司 | 用于癌症治疗的载体 |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9711957D0 (en) | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
| EP1200622A4 (en) | 1999-07-06 | 2004-12-22 | Merck & Co Inc | HIV VACCINE FROM AN ADENOVIRUS CARRYING THE GAG GENE |
| US6733993B2 (en) | 2000-09-15 | 2004-05-11 | Merck & Co., Inc. | Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications |
| GB0118532D0 (en) * | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
| WO2003097087A1 (en) * | 2002-05-20 | 2003-11-27 | Japan Science And Technology Agency | Bcg vaccine and utilization thereof |
| US20080153083A1 (en) | 2003-10-23 | 2008-06-26 | Crucell Holland B.V. | Settings for recombinant adenoviral-based vaccines |
| EP1553983A2 (en) | 2002-10-23 | 2005-07-20 | Crucell Holland B.V. | New settings for recombinant adenoviral-based vaccines |
| AU2007322075B2 (en) * | 2006-11-17 | 2013-07-25 | Genetronics, Inc. | Methods of enhancing immune response using electroporation-assisted vaccination and boosting |
| GB0706912D0 (en) * | 2007-04-10 | 2007-05-16 | Isis Innovation | Novel viral vaccines |
| GB0706914D0 (en) | 2007-04-10 | 2007-05-16 | Isis Innovation | Novel adenovirus vectors |
| JP5710254B2 (ja) * | 2007-09-14 | 2015-04-30 | アンスティテュ・パストゥールＩｎｓｔｉｔｕｔ Ｐａｓｔｅｕｒ | 外来エピトープを含む組換え偽ウイルスの発現および分泌を可能とするポリヌクレオチド、それらの製造および使用 |
| GB0823497D0 (en) * | 2008-12-24 | 2009-01-28 | Isis Innovation | Immunogenic composition and use thereof |
| KR20230166145A (ko) | 2017-03-15 | 2023-12-06 | 옥스포드 바이오메디카(유케이) 리미티드 | 방법 |
| US20230310591A1 (en) | 2021-12-07 | 2023-10-05 | Vaccitech (Uk) Limited | Vaccine Boost Methods and Compositions |
| WO2024218165A1 (en) | 2023-04-17 | 2024-10-24 | Barinthus Biotherapeutics (Uk) Limited | Hpv viral vector vaccine |
-
1999
- 1999-09-21 GB GBGB9922361.2A patent/GB9922361D0/en not_active Ceased
-
2000
- 2000-09-20 CN CN00815933A patent/CN1391609A/zh active Pending
- 2000-09-20 WO PCT/GB2000/003601 patent/WO2001021201A2/en not_active Ceased
- 2000-09-20 CA CA002384806A patent/CA2384806A1/en not_active Abandoned
- 2000-09-20 AT AT00960857T patent/ATE295421T1/de not_active IP Right Cessation
- 2000-09-20 EP EP05009308A patent/EP1612269A1/en not_active Withdrawn
- 2000-09-20 DK DK00960857T patent/DK1214416T3/da active
- 2000-09-20 ES ES00960857T patent/ES2241653T3/es not_active Expired - Lifetime
- 2000-09-20 EP EP00960857A patent/EP1214416B1/en not_active Revoked
- 2000-09-20 DE DE60020136T patent/DE60020136T2/de not_active Revoked
- 2000-09-20 AU AU73024/00A patent/AU762894B2/en not_active Ceased
- 2000-09-20 JP JP2001524625A patent/JP2003509470A/ja not_active Withdrawn
- 2000-09-20 BR BR0014138-0A patent/BR0014138A/pt not_active Application Discontinuation
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100410382C (zh) * | 2006-08-18 | 2008-08-13 | 上海交通大学医学院 | 一种可诱生细胞免疫应答的共表达载体和真核表达载体 |
| CN104755622A (zh) * | 2012-10-28 | 2015-07-01 | 巴法里安诺迪克有限公司 | 用于稳健t细胞和抗体应答的pr13.5启动子 |
| CN104755622B (zh) * | 2012-10-28 | 2021-04-20 | 巴法里安诺迪克有限公司 | 用于稳健t细胞和抗体应答的pr13.5启动子 |
| CN114828878A (zh) * | 2019-10-16 | 2022-07-29 | 癌症研究科技有限公司 | 用于癌症治疗的载体 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1612269A1 (en) | 2006-01-04 |
| BR0014138A (pt) | 2002-05-21 |
| EP1214416A2 (en) | 2002-06-19 |
| AU762894B2 (en) | 2003-07-10 |
| WO2001021201A2 (en) | 2001-03-29 |
| EP1214416B1 (en) | 2005-05-11 |
| DE60020136T2 (de) | 2006-02-23 |
| DK1214416T3 (da) | 2005-08-29 |
| WO2001021201A3 (en) | 2001-10-18 |
| AU7302400A (en) | 2001-04-24 |
| JP2003509470A (ja) | 2003-03-11 |
| DE60020136D1 (de) | 2005-06-16 |
| ES2241653T3 (es) | 2005-11-01 |
| ATE295421T1 (de) | 2005-05-15 |
| CA2384806A1 (en) | 2001-03-29 |
| GB9922361D0 (en) | 1999-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1335023B1 (en) | Methods and reagents for vaccination which generate a CD8 T cell immune response | |
| CN1391609A (zh) | 用复制缺陷腺病毒载体加强cd8+t细胞对抗原的免疫应答 | |
| Gilbert et al. | Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime–boost immunisation regimes | |
| US11065320B2 (en) | Prime target | |
| AU775973B2 (en) | Methods and reagents for vaccination which generate a CD8 T cell immune response | |
| US11013791B2 (en) | NYVAC-based plasmodium malaria vaccine | |
| AU2004203141B2 (en) | Methods and reagents for vaccination which generate CD8 T cell immune response | |
| Sawant | DEEMED UNIVERSITY |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| AD01 | Patent right deemed abandoned | ||
| C20 | Patent right or utility model deemed to be abandoned or is abandoned |